How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure

The evaluation and use of patient reported outcome (PRO) measures requires detailed understanding of the meaning of the outcome of interest. The Food and Drug Administration (FDA) recently presented its draft guidance and view on the use of PRO measures as endpoints in clinical trials. One section o...

Descripción completa

Detalles Bibliográficos
Autores principales: Brożek, Jan L, Guyatt, Gordon H, Schünemann, Holger J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1599713/
https://www.ncbi.nlm.nih.gov/pubmed/17005037
http://dx.doi.org/10.1186/1477-7525-4-69

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1599713/
https://www.ncbi.nlm.nih.gov/pubmed/17005037
http://dx.doi.org/10.1186/1477-7525-4-69

Ejemplares similares